ClinicalTrials.gg
RecruitingNCT07704099Updated Nov 13, 2026

Safety and Efficacy of KER-065 in Participants With Duchenne Muscular Dystrophy

A Phase 2 interventional study of KER-065 in Duchenne Muscular Dystrophy, sponsored by Keros Therapeutics, Inc.. Recruiting at 4 sites in 2 countries. Open to male participants aged 9 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Keros Therapeutics, Inc. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Nov 13, 2026Now RecruitingFirst sites in New Zealand and Georgia+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
9 Years and older
Sex
Male
01

Study summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of KER-065 administered to adult and pediatric ambulatory and nonambulatory male participants with Duchenne Muscular Dystrophy (DMD) on stable background therapy.

Read the detailed description

This is a Phase 2, multicenter, open-label study of KER-065.

The study will consist of 3 periods:

  • Screening Period (up to 6 weeks)
  • Treatment Period (48 weeks)
  • Safety Follow-up Period (4 weeks)

Participants will be enrolled in parallel into 1 of 3 treatment cohorts:

  • Cohort A1 (Late Ambulatory)
  • Cohort A2 (Late Ambulatory)
  • Cohort N1 (Early Nonambulatory)
02

Conditions studied

  • Duchenne Muscular Dystrophy

Keywords

  • Recombinant fusion protein
  • Muscle-wasting disease
  • Ambulatory function
  • Pharmacokinetics
  • Pharmacodynamics
03

In context

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

This study's planned enrollment of 36 is above the median of 25 across 333 interventional studies indexed under Muscular Dystrophy, Duchenne.

Browse Muscular Dystrophy, Duchenne studies →

Lead sponsor

Keros Therapeutics, Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
9 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosis of DMD, defined as the presence of phenotypic features at screening consistent with DMD AND documented mutation in the dystrophin gene consistent with the diagnosis of DMD using a clinically validated genetic test.
  • Receiving a stable regimen of systemic CS (including, but not limited to, prednisone, prednisolone, deflazacort, or vamorolone) for at least 90 days before screening.
  • Body weight of ≥ 25.0 kg.

Ambulatory Participants Only (Cohort A1 and A2):

  • Ambulatory, defined as able to walk independently without assistive devices.
  • Able to TTR in \< 10 seconds.
  • Has a NSAA score ≥ 15 points.
  • Cohort 2 only: Documentation of a stable dose of an approved exon-skipping therapy.

Nonambulatory Participants Only (Cohort N1):

  • Nonambulatory, characterized as being unable to ambulate for a minimum of 3 months before first dose with onset of nonambulatory status AND a NSAA walk score of 0 and inability to perform the 10MWR.
  • PUL v2.0 entry item score of 3 to 5, inclusive.

Key Exclusion Criteria:

  • Clinical symptoms or signs of cardiomyopathy or heart failure.
  • Exposure to any approved or dystrophin restoration gene therapy product.
  • Exposure to any approved or investigational dystrophin restoration product other than gene therapy (Except for exon-skipping therapy for Cohort A2).
  • Exposure to any approved or investigational histone deacetylase inhibitor, antimyostatin therapy, therapy targeting transforming growth factor-beta ligands, or cell-based therapy.
  • Use of any other pharmacological treatment, except for CS
  • Treatment with therapy (other than CS)
  • History of fracture of the upper limb

Nonambulatory Participants Only (Cohort N1):

  • Elbow-flexion contractures > 30° in both upper extremities.
  • Forced vital capacity (FVC) of \< 50% or requirement for daytime or nocturnal ventilation, except for nocturnal non-invasive ventilation AND inability to perform consistent FVC measurements within ± 15% during paired testing.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Cohort A1 (Late Ambulatory)

    Participants will receive stable corticosteroid (CS) along with KER-065.

    Drug: KER-065

  • Experimental
    Cohort A2 (Late Ambulatory)

    Participants will receive stable CS, exon skipper along with KER-065.

    Drug: KER-065

  • Experimental
    Cohort N1 (Early Nonambulatory)

    Participants will receive stable CS along with KER-065.

    Drug: KER-065

Interventions

  • DrugKER-065

    KER-065 will be administered subcutaneously (SC)

    Also known as: Rinvatercept

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-emergent adverse events (TEAEs and serious adverse events (SAEs)

    To evaluate the safety and tolerability of KER-065 in ambulatory and nonambulatory participants with DMD

    Time frame: Up to approximately 14 months

Secondary outcomes

  1. KER-065 serum concentration by visit, as appropriate

    To assess the pharmacokinetics (PK) of KER-065 in ambulatory and nonambulatory participants with DMD

    Time frame: Up to Week 52

  2. Number and proportion of participants with treatment-emergent ADA (antidrug antibody) by visit

    To assess the immunogenicity of KER-065 in ambulatory and nonambulatory participants with DMD

    Time frame: Up to Week 52

  3. Change from baseline by visit in bone mineral density (BMD), fat mass, and lean body mass, as measured by dual- energy X-ray absorptiometry (DXA)

    To assess the effect of KER-065 on body composition in ambulatory and nonambulatory participants with DMD

    Time frame: Week 12, Week 24 and Week 48

  4. Change from baseline by visit in muscle volume and intramuscular fat by skeletal muscle Magnetic Resonance Imaging (MRI)

    To assess the effect of KER-065 on skeletal muscle in ambulatory and nonambulatory participants with DMD

    Time frame: Week 24 and Week 48

  5. Ambulatory: Change from baseline by visit in North Star Ambulatory Assessment (NSAA) total score

    To assess the effect of KER-065 on motor function in ambulatory participants with DMD

    Time frame: Week 24 and Week 48

  6. Ambulatory: Change from baseline by visit in 4-stair climb (4SC)

    To assess the effect of KER-065 on motor function in ambulatory participants with DMD

    Time frame: Week 24 and Week 48

  7. Ambulatory: Change from baseline by visit in 10-meter walk/run (10MWR) test

    To assess the effect of KER-065 on motor function in ambulatory participants with DMD

    Time frame: Week 24 and Week 48

  8. Ambulatory: Change from baseline by visit in time to rise (TTR)

    To assess the effect of KER-065 on motor function in ambulatory participants with DMD

    Time frame: Week 24 and Week 48

  9. Nonambulatory: Change from baseline by visit in Performance of Upper Limb (PUL) v2.0 score

    To assess the effect of KER-065 on motor function in nonambulatory participants with DMD

    Time frame: Week 24 and Week 48

07

Study locations

2 of 4 sites recruiting
  • LTD TIM - Tbilisi Institute of Medicine
    Tbilisi, 0160, Georgia
    Not yet recruiting
  • Institute of Neurology and Neuropsychology LTD
    Tbilisi, 0186, Georgia
    Not yet recruiting
  • Optimal Clinical Trials
    Auckland, North Island 1010, New Zealand
    Recruiting
  • NZCR-Christchurch
    Christchurch, South Island 8011, New Zealand
    Recruiting
08

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Aug 2028, 23 months after the start.

Of 40 industry-sponsored phase 2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 42. This study's planned 23 months is below that.

Counting every sponsor, half of 47 studies reached it within 31 months; a quarter within 20 and three quarters within 42.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Jul 2029 → Aug 2028 and completion Aug 2029 → Sep 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2026
First posted
Jul 15, 2026
StartActual
Sep 25, 2026
Primary completionEst.
Aug 26, 2028was Jul 2029
CompletionEst.
Sep 23, 2028was Aug 2029
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 30, 2026
Sites
4 sites added — first sites in New Zealand and Georgia
Show 4 added (2 New Zealand, 2 Georgia)
  • Optimal Clinical Trials · Auckland, New Zealand
  • NZCR-Christchurch · Christchurch, New Zealand
  • LTD TIM - Tbilisi Institute of Medicine · Tbilisi, Georgia
  • Institute of Neurology and Neuropsychology LTD · Tbilisi, Georgia
across 2 updates, Sep 30, 2026 – Nov 4, 2026
Start date
Sep 14, 2026→Sep 25, 2026 (actual)
Sep 30, 2026
Primary completion
Jul 17, 2029→Aug 26, 2028
Sep 30, 2026
Study completion
Aug 14, 2029→Sep 23, 2028
Sep 30, 2026
Contact
Study contact changed: g•••@kerostx.com · •••3345→e•••@kerostx.com · •••6297. See the current contact
Nov 13, 2026
Show all 3 updates
  1. Nov 13, 2026
    Contact Study contact changed: g•••@kerostx.com · •••3345→e•••@kerostx.com · •••6297. See the current contact
    + 1 other change: verification date
  2. Nov 4, 2026
    2 sites added — first site in Georgia
    Show 2 added (2 Georgia)
    • LTD TIM - Tbilisi Institute of Medicine · Tbilisi, Georgia
    • Institute of Neurology and Neuropsychology LTD · Tbilisi, Georgia
    + 1 other change: verification date
  3. Sep 30, 2026
    Not yet recruiting→Recruiting
    2 sites added — first site in New Zealand
    Show 2 added (2 New Zealand)
    • Optimal Clinical Trials · Auckland, New Zealand
    • NZCR-Christchurch · Christchurch, New Zealand
    Start date Sep 14, 2026→Sep 25, 2026 (now actual)
    Primary completion Jul 17, 2029→Aug 26, 2028
    Study completion Aug 14, 2029→Sep 23, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07704099
Lead sponsor
Keros Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jul 15, 2026
Start date
Sep 25, 2026
Primary completion
Aug 26, 2028 (estimated)
Completion
Sep 23, 2028 (estimated)
Last update
Nov 13, 2026

Study contacts

Eleni Tsiroyannis
Contact
etsiroyannis@kerostx.com
(617) 314-6297

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion (1)

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

WAELQuestion

طريقة تسجيل في دراسه لطفلي

1 comment